We are live on
!
Find out more
EAM
Exome Asset Management Portfolio holdings
AUM
$193M
1-Year Est. Return
208.51%
This Fund
S&P 500
This Quarter
Est. Return
+82%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$209M
AUM Growth
+$44M
(+27%)
Cap. Flow
-$21.4M
Cap. Flow
% of AUM
-10.24%
Top 10 Holdings %
Top 10 Hldgs %
42.68%
Holding
94
New
26
Increased
5
Reduced
16
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$5.81M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$4.8M |
| 3 |
Enliven Therapeutics
ELVN
|
+$4.43M |
| 4 |
Wave Life Sciences
WVE
|
+$4.28M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$4.06M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$8.17M |
| 2 |
NBP
NovaBridge Biosciences American Depositary Shares
NBP
|
+$4.16M |
| 3 |
ETNB
89bio
ETNB
|
+$4.02M |
| 4 |
Cogent Biosciences
COGT
|
+$3.88M |
| 5 |
Apogee Therapeutics
APGE
|
+$3.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Arrowhead Research
ARWR
$12.3B
| $3.3M | 1.58% |
49,758
-54,749
| -52% | -$2.68M |
|
27
CytomX Therapeutics
CTMX
$714M
| $3.17M | 1.52% |
745,305
| – | – |
|
28
Liquidia Corp
LQDA
$7.72B
| $3.14M | 1.5% |
91,148
-3,087
| -3% | -$87.9K |
|
29
Verastem
VSTM
$536M
| $3.1M | 1.48% |
+401,743
| New | +$3.58M |
|
30
PUT
Travere Therapeutics
TVTX
$5.33B
| $2.85M | 1.36% |
+74,700
| New | +$2.43M |
|
|
ALMS
31
Alumis Inc
ALMS
$3.69B
| $2.85M | 1.36% |
292,250
-520
| -0.2% | -$3.63K |
|
32
Penumbra
PEN
$12.6B
| $2.8M | 1.34% |
9,000
| – | – |
|
33
10x Genomics
TXG
$6.28B
| $2.67M | 1.28% |
163,658
| – | – |
|
34
Immunocore
IMCR
$1.72B
| $2.66M | 1.27% |
+76,750
| New | +$2.71M |
|
35
Edgewise Therapeutics
EWTX
$4.42B
| $2.48M | 1.19% |
100,046
-73,393
| -42% | -$1.47M |
|
36
NextCure
NXTC
$20.5M
| $2.34M | 1.12% |
+165,000
| New | +$1.71M |
|
|
BLTE
37
Belite Bio
BLTE
$6.41B
| $2.29M | 1.1% |
+14,328
| New | +$1.7M |
|
|
WAY
38
Waystar Holding Corp
WAY
$4.02B
| $2.26M | 1.08% |
68,969
+22,069
| +47% | +$786K |
|
39
Ironwood Pharmaceuticals
IRWD
$614M
| $2.19M | 1.05% |
+648,532
| New | +$1.68M |
|
40
Karyopharm Therapeutics
KPTI
$159M
| $2.18M | 1.04% |
+295,541
| New | +$1.81M |
|
|
ADAG
41
Adagene
ADAG
$246M
| $2M | 0.96% |
+1,060,221
| New | +$1.96M |
|
|
NBP
42
NovaBridge Biosciences American Depositary Shares
NBP
$190M
| $1.99M | 0.95% |
499,587
-940,017
| -65% | -$4.16M |
|
43
UnitedHealth
UNH
$383B
| $1.93M | 0.92% |
+5,835
| New | +$1.98M |
|
44
Palisade Bio
PALI
$341M
| $1.78M | 0.85% |
+758,203
| New | +$1.46M |
|
|
UPB
45
Upstream Bio Inc
UPB
$358M
| $1.76M | 0.84% |
64,845
+12,885
| +25% | +$321K |
|
46
Gossamer Bio
GOSS
$87.2M
| $1.4M | 0.67% |
451,699
| – | – |
|
47
PUT
Disc Medicine
IRON
$3.03B
| $1.27M | 0.61% |
+16,000
| New | +$1.35M |
|
48
Inhibikase Therapeutics
IKT
$358M
| $1.23M | 0.59% |
+600,000
| New | +$955K |
|
49
IQVIA
IQV
$39.1B
| $1.21M | 0.58% |
+5,378
| New | +$1.17M |
|
50
Tenet Healthcare
THC
$21.8B
| $1.21M | 0.58% |
6,084
-12,016
| -66% | -$2.43M |
|
Similar funds
WWC
JHA
TDWM
DF
SCM
PA
SCPM
EWM
Exome Asset Management's Q4 2025 Portfolio in Review
As of Q4 2025, Exome Asset Management held 94 positions worth $209M, up 27% from $165M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Exome Asset Management withdrew a net $21.4M in Q4 2025, closing 34 positions and reducing 16 holdings. Its most notable exit was 89bio, an estimated $4.02M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier.
Against the trend, Exome Asset Management opened a new position in Elevance Health worth $6.03M.
- Exome Asset Management's largest Q4 2025 buy was Elevance Health: 17,191 shares worth $6.03M.
- Exome Asset Management added most to Universal Health Services in Q4 2025, an estimated $2.14M increase.
- Exome Asset Management's biggest Q4 2025 reduction was Praxis Precision Medicines, cutting an estimated $8.17M.
- Exome Asset Management fully exited 89bio in Q4 2025, selling an estimated $4.02M.
- Exome Asset Management's ten largest holdings make up 43% of its $209M portfolio in Q4 2025.
- Exome Asset Management opened 26 new positions and closed 34 in Q4 2025.
- Exome Asset Management's portfolio value rose 27% quarter-over-quarter to $209M.
Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.